Q32 Bio Inc. (NASDAQ: QTTB) completed a registered direct offering of 1,666,679 shares of common stock and pre‑funded warrants to purchase up to 1,025,654 shares at $3.90 per share, raising $10.5 million. The transaction closed on February 18 2026 and will be combined with the company’s existing cash and marketable securities to extend its operating runway into 2027.
The capital raised will support ongoing research, clinical development, and commercialization activities for the company’s lead asset, bempikibart, an anti‑IL‑7Rα antibody that has received FDA Fast Track designation for alopecia areata. Bempikibart is currently in Phase 2 trials, with topline data from the SIGNAL‑AA Part B study expected in mid‑2026. The additional funding is intended to bridge the company through this critical data release and to maintain momentum toward regulatory submission.
Q32 Bio also recently sold its complement inhibitor ADX‑097 to Akebia Therapeutics for a $12 million upfront payment and potential milestone payments. The proceeds from that transaction, combined with the direct offering, provide a robust cash cushion that supports the company’s projected milestones through the second half of 2027. Management has emphasized that the combined resources will allow the company to focus on bempikibart’s development without the need for further immediate capital raises.
The offering reflects the company’s strategy to prioritize bempikibart, which the CEO has described as a potential paradigm shift for alopecia areata treatment. By securing additional capital, Q32 Bio aims to sustain its clinical program, manage cash burn, and position itself for a possible regulatory filing once the Phase 2 data are available.
The direct offering underscores Q32 Bio’s commitment to advancing its flagship therapy while maintaining financial flexibility in a competitive therapeutic area with significant unmet need.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.